Partnering

ACADIA is committed to the discovery and development of novel treatments for CNS disorders. Our current preclinical and clinical programs all emanate from internal discoveries and are rooted in our scientific heritage and strength in CNS research.

Core to ACADIA's strategy is to pursue strategic collaborations. In CNS areas that involve more extensive development or require a large sales force, we intend to complete late-stage clinical development and commercialization in collaboration with partners. In CNS areas where our products can be commercialized by a specialty sales force, we plan to retain selected commercialization rights. Additionally, for discoveries we have made that have applications outside our main focus area, we may explore partnerships earlier in the process to accelerate advancements of these programs.

To further explore partnering opportunities with ACADIA, please contact us at bd@acadia-pharm.com.

Current Partnerships

Allergan

ACADIA has formed three separate collaborations with Allergan in the areas of pain and ophthalmology:

• The first collaboration has resulted in the discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain. Allergan is conducting Phase II trials in this program.
• In the second collaboration, Allergan and ACADIA are focused on the development and commercialization of selective muscarinic drugs for the treatment of glaucoma. Allergan is conducting an exploratory clinical trial in this program.
• The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.